Vir Biotechnology Appoints New CFO Aziz Sawaf

What Happened
Vir Biotechnology (VIR) announced in an 8-K filed Oct 1, 2026 that Aziz Sawaf, MBEE, MBA, CFA has been hired as Executive Vice President and Chief Financial Officer, effective Oct 5, 2026. Brent Sabatini will stop serving as interim principal financial officer on the Effective Date and will continue as Senior Vice President and Chief Accounting Officer and principal accounting officer. The company issued a press release on Oct 1, 2026 announcing the appointment.

Key Details

• Effective Date: October 5, 2026; 8-K filed and press release dated October 1, 2026.
• Compensation: $520,000 annualized base salary; target annual bonus = 45% of base salary; $150,000 one-time cash sign-on bonus (50% at start, 50% after 1 year, subject to continued employment).
• Equity: On or around Nov 15, 2026 (Grant Date) Vir will grant an option for 150,000 shares and RSUs for 75,000 shares. Option exercise price = fair market value on Grant Date; both awards vest over four years (25% after one year; remainder monthly for options / annually for RSUs).
• Severance (under Vir’s existing Severance Plan): covered termination within 12 months after a change in control = 12 months base salary + annual target bonus + up to 12 months COBRA-like health payments + full equity acceleration; covered termination outside change-in-control period = 9 months base salary + pro‑rated bonus + up to 9 months health payments.
• Background: Mr. Sawaf, 44, served as CFO at Theravance Biopharma since 2023 and held finance roles at Theravance (joined 2014) and Gilead Sciences; degrees from Univ. of Arizona (BS), USC Marshall (MBA), Johns Hopkins (MBEE); CFA charterholder. No related-party transactions or family relationships were disclosed.

Why It Matters
A permanent CFO appointment ends an interim period and provides investors clarity on financial leadership and succession. The compensation and equity package aligns Mr. Sawaf’s financial incentives with shareholder outcomes over a multi‑year period, while the severance terms outline potential post-change‑in‑control and termination protections. Investors may view this as governance and management stability; the filing also notes the company will include the offer letter as an exhibit in its upcoming Form 10-Q.